DNA Stock Risk & Deep Value Analysis
Ginkgo Bioworks Holdings Inc
DVR Score
out of 10
What You Need to Know About DNA Stock
We analyzed Ginkgo Bioworks Holdings Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran DNA through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
DNA Risk Analysis & Red Flags
What Could Go Wrong
Ginkgo's core cell engineering revenue could continue to decline or stagnate despite strategic pivots, making it impossible to achieve profitability or the substantial growth needed to justify its vision. The heavy cash burn implied by the -$10.02 FY26 EPS forecast highlights the risk of ongoing value destruction and potential for significant shareholder dilution if the turnaround is unsuccessful.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
Medium
Execution
High
Regulatory
Low
Red Flags
- ⚠
FY26 EPS forecast of -$10.02 indicates severe ongoing unprofitability.
- ⚠
Nasdaq filing deficiency notice for delayed quarterly report (Form 10-Q).
- ⚠
Core cell engineering revenue experienced decline in Q4 2025.
- ⚠
Major institutional investor Baillie Gifford & Co. reduced position by 26.1%.
Upcoming Risk Events
- 📅
Continued decline or stagnation in core cell engineering revenue
- 📅
Failure to significantly reduce cash burn rates or need for dilutive capital raise
- 📅
Further delays in SEC filings or compliance issues (e.g., Nasdaq delisting threat)
- 📅
Intensified competition from other synthetic biology platforms or traditional CROs
When to Reconsider
- 🚪
Quarterly cell engineering revenue (post-Biosecurity divestiture) continues to decline or remains stagnant for two consecutive quarters.
- 🚪
Cash burn rates fail to improve substantially or worsen significantly beyond current guidance.
- 🚪
New equity raises cause substantial dilution (e.g., >15-20% of outstanding shares in a single transaction).
- 🚪
Ginkgo fails to resolve its Nasdaq filing deficiency or faces further compliance issues.
Unlock DNA Risk Analysis & Red Flags
Create a free account to see the full analysis
Investment Thesis
Ginkgo Bioworks is a high-risk, high-reward investment betting on its 'AWS for biology' vision to become the dominant infrastructure provider for synthetic biology. The strategic pivot to focus solely on its core cell engineering platform, coupled with significant investments in autonomous labs and the Cloud Lab, strengthens its long-term positioning. Despite current financial headwinds (revenue decline, heavy losses, negative FY26 EPS outlook), the expanding data moat and scalable business model offer multi-bagger potential if execution dramatically improves cash flow and eventually drives exponential platform adoption and market leadership.
Is DNA Stock Undervalued?
Unlock the full AI analysis for DNA
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
DNA Price Targets & Strategy
12-Month Target
$10.00
Bull Case
$15.00
Bear Case
$5.00
Valuation Basis
Based on 5.0x forward P/S applied to estimated FY26 revenue of $120M (reflecting post-divestiture core business, assuming stabilization).
Entry Strategy
Dollar-cost average between $6.00-$7.00, targeting dips towards the 52-week low of $5.00, which aligns with InvestingPro's 'undervalued' assessment.
Exit Strategy
Take initial profit at $15.00 (approaching previous 52-week highs), consider full exit if the long-term 10x target of ~$80.00 is achieved within 3-5 years. Implement a strict stop-loss at $5.00 to manage downside risk.
Portfolio Allocation
1-3% for aggressive investors only, given extreme volatility and significant financial and execution risks.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is DNA Financially Healthy?
Valuation
P/E Ratio
-1.14
Profitability
Gross Margin
72.39%
Operating Margin
-194.89%
Net Margin
-183.81%
Return on Equity
-53.72%
Revenue Growth
-25.06%
EPS
$-5.64
Balance Sheet
Current Ratio
4.92
Quick Ratio
4.73
Cash Flow
Operating Cash Flow
-$173.65M
Other
Beta (Volatility)
1.70
Does DNA Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
3 Identified
Ginkgo's moat could persist for 10-20 years if it successfully scales its automated platform, continually expands its biological dataset, and attracts a critical mass of customers, making its integrated capabilities increasingly superior and difficult for competitors to replicate due to high upfront investment and technical complexity.
Moat Erosion Risks
- •Competitors developing alternative or superior automated synthetic biology platforms
- •Customers opting for in-house R&D solutions or traditional contract research organizations (CROs)
- •Failure to effectively monetize the platform or demonstrate superior ROI to customers
DNA Competitive Moat Analysis
Sign up to see competitive advantages
DNA Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral to slightly Bearish. While the 'AWS for biology' vision garners some long-term optimism, current financial performance and market sentiment keep retail interest subdued.
Institutional Sentiment
Negative. Analyst consensus is 'Reduce' with recent downgrades and a major institutional holder (Baillie Gifford) significantly reducing its stake.
Insider Activity (Form 4)
CFO Steven P. Coen sold 33,171 shares (~$212,758) on April 13, 2026, for tax withholding. Director Reshma P. Shetty sold 124,727 shares (~$801,000) on April 9, 2026, for tax withholding. Major shareholder Barry Canton (spouse) sold 124,727 shares (~$798,000) on April 9, 2026, for tax withholding. All recent insider sales are routine equity compensation tax withholdings, not discretionary sales.
Options Flow
Normal options activity. No unusual institutional positioning or significant skew in put/call ratios identified from the research.
Earnings Intelligence
Next Earnings
Estimated late May 2026 (for Q1 2026)
Surprise Probability
Medium. While Q4 2025 EPS beat estimates, revenue missed, and the company operates with high volatility and unprofitability, making predictions challenging.
Historical Earnings Pattern
The stock has historically exhibited high volatility around earnings reports, often reacting more intensely to changes in cash burn guidance, strategic updates, and long-term outlook than to specific quarterly revenue beats or misses.
Key Metrics to Watch
Competitive Position
Top Competitor
Recursion Pharmaceuticals (RXRX)
Market Share Trend
Losing ground in terms of reported revenue within its core cell engineering segment, but actively working to gain overall market share for its platform-based approach.
Valuation vs Peers
Ginkgo's Price/Sales ratio (approx. 3.6x) is relatively low for a 'growth' biotech, reflecting its current revenue decline and deep unprofitability. Many peers, even unprofitable ones, trade at higher P/S multiples if they demonstrate faster revenue growth or a clearer path to commercialization.
Competitive Advantages
- •Proprietary automated biological foundry and software platform ('Ginkgo Foundry')
- •Extensive and growing proprietary biological code library/data assets
- •Horizontal platform model applicable across diverse industries
- •Significant scale advantage in high-throughput biological experimentation
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive DNA Stock Higher?
Near-Term (0-6 months)
- •Q1 2026 Earnings report (estimated late May 2026)
- •Further adoption and feature expansion of Ginkgo Cloud Lab
- •Updates on scaling Autonomous Labs (RAC cart expansion to 100 systems by EOY 2026)
Medium-Term (6-18 months)
- •Demonstrated stabilization or growth in core cell engineering revenue
- •Significant reduction in cash burn and narrowing of operating losses
- •New strategic customer programs or partnerships leveraging the Cloud Lab
Long-Term (18+ months)
- •Achievement of consistent positive free cash flow and profitability
- •Establishment as the dominant 'AWS for biology' platform
- •Successful development and commercialization of high-value programs on the platform
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for DNA?
- ✓
Acceleration in new customer program adds and successful conversion to downstream milestones/royalties.
- ✓
Sustained quarter-over-quarter growth in core cell engineering revenue (post-Biosecurity divestiture).
- ✓
Significant and consistent reduction in free cash flow burn, leading to a clear path to FCF positivity.
Bull Case Analysis
See what could go right with Premium
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Ginkgo Bioworks Holdings Inc Makes Money
Ginkgo Bioworks operates as a 'foundry for biology,' providing a platform for customers to program cells for various applications, analogous to how semiconductor foundries produce chips. It leverages advanced automation, robotics, and proprietary software to design, build, and test biological systems at scale. Customers, spanning industries from pharmaceuticals to food and fragrance, utilize Ginkgo's platform to develop new products or processes. Rather than solely traditional fee-for-service, Ginkgo frequently aligns incentives by taking equity stakes or future royalty payments from successful products developed using its platform, betting on the long-term success of its partners.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Ginkgo Bioworks Holdings Inc (DNA)?
As of April 21, 2026, Ginkgo Bioworks Holdings Inc has a DVR Score of 5.9 out of 10, placing it in the "Proceed with Caution" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Ginkgo Bioworks Holdings Inc?
Ginkgo Bioworks Holdings Inc's market capitalization is approximately $492.7M..
What is the risk level for DNA stock?
Our analysis rates Ginkgo Bioworks Holdings Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of DNA?
Ginkgo Bioworks Holdings Inc currently has a price-to-earnings (P/E) ratio of -1.1. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Ginkgo Bioworks Holdings Inc's revenue growing?
Ginkgo Bioworks Holdings Inc has reported revenue growth of -25.1%. Revenue has been declining, which warrants closer examination.
Is DNA stock profitable?
Ginkgo Bioworks Holdings Inc has a profit margin of -183.8%. The company is currently unprofitable.
How often is the DNA DVR analysis updated?
Our AI-powered analysis of Ginkgo Bioworks Holdings Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on April 21, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for DNA (Ginkgo Bioworks Holdings Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.